Wegovy vs Saxenda: Long-Term Durability of Response

How Much Weight Do These Two Drugs Actually Produce?

Semaglutide 2.4 mg (Wegovy) delivers approximately double the weight loss of liraglutide 3 mg (Saxenda) in head-to-head and parallel trial data. That gap is not subtle. STEP-8 (N=338), published in JAMA in 2022, directly randomized adults with overweight or obesity to semaglutide 2.4 mg weekly or liraglutide 3 mg daily for 68 weeks. Semaglutide produced 15.8% mean body-weight loss; liraglutide produced 6.4%. [1]

STEP-1 Data for Semaglutide

In STEP-1 (N=1,961), adults without diabetes received semaglutide 2.4 mg weekly or placebo alongside lifestyle intervention for 68 weeks. Mean weight loss was 14.9% in the semaglutide group versus 2.4% in the placebo group (P<0.001). [2] Roughly 86% of participants lost at least 5% of body weight, and 50% lost 15% or more.

SCALE Data for Liraglutide

The SCALE Obesity and Prediabetes trial (N=3,731) evaluated liraglutide 3 mg daily for 56 weeks. Mean weight loss reached 8.4% versus 2.8% with placebo (P<0.001). [3] Approximately 63% of liraglutide participants lost 5% or more of baseline weight, compared with 27% on placebo.

Both numbers are clinically meaningful reductions. Still, the 6-to-9 percentage-point advantage for semaglutide compounds over time, particularly in patients who need to reach a threshold weight for orthopedic surgery candidacy or glycemic remission.

Long-Term Durability: What Happens After the Trial Ends?

Weight regain after stopping either GLP-1 receptor agonist is substantial, predictable, and begins within weeks. Neither drug cures obesity; they suppress appetite through receptor signaling that reverses on discontinuation. The question for clinical planning is not whether weight returns, but how fast and how much.

Wegovy Durability After Discontinuation

STEP-4 (N=803) provides the clearest picture for semaglutide. Participants who achieved a mean 10.6% weight loss during a 20-week semaglutide run-in were then randomized to continue semaglutide or switch to placebo for another 48 weeks. [4] Those who continued semaglutide lost an additional 7.9% of body weight. Those switched to placebo regained 6.9 percentage points of their baseline weight by week 68. The net difference between the groups was approximately 14 percentage points at trial end. The FDA label for Wegovy notes that weight regain typically begins within weeks of stopping. [5]

Saxenda Durability After Discontinuation

Liraglutide's durability data come primarily from the SCALE Maintenance trial (N=422), which enrolled patients who had already lost at least 5% body weight on a low-calorie diet. Over 56 weeks, liraglutide 3 mg maintained a 6.2% additional loss versus 0.2% on placebo. [6] After stopping, weight regain in observational follow-up data tends to occur faster than with semaglutide, likely because liraglutide's shorter half-life (13 hours versus semaglutide's approximately 7 days) means receptor engagement drops off more rapidly. Patients in the SCALE program who discontinued early tended to return toward baseline weight within 12 weeks in clinical practice cohorts.

A Framework for Thinking About Durability

Durability of response depends on three factors: magnitude of initial loss, half-life of the drug, and behavioral anchoring achieved during treatment. Semaglutide scores higher on the first two. Liraglutide may provide an advantage in patients who need more flexible titration or who cannot tolerate semaglutide's slower escalation schedule, but that flexibility comes at a cost in sustained efficacy. Patients who stop either drug without transitioning to another weight-management intervention should expect meaningful regain within 3 to 12 months.

Head-to-Head Evidence: STEP-8 in Detail

STEP-8 is the only randomized controlled trial that directly compared these two specific formulations in adults with obesity or overweight. [1] Published in JAMA in 2022, it enrolled 338 adults (mean BMI 37.8 kg/m²) at 19 U.S. Sites. Both drugs were titrated to their approved maximum doses: semaglutide to 2.4 mg weekly and liraglutide to 3 mg daily. All participants received behavioral counseling.

Primary Outcome

At 68 weeks, semaglutide produced 15.8% mean weight loss versus 6.4% for liraglutide. The difference of 9.4 percentage points was statistically significant (P<0.001). More than 70% of semaglutide participants lost at least 10% of body weight, compared with 25% on liraglutide. [1]

Tolerability and Dropout

Gastrointestinal adverse events were common in both groups. Nausea affected approximately 44% of semaglutide participants and 40% of liraglutide participants. Discontinuation due to adverse events was 3.5% for semaglutide and 7.5% for liraglutide in STEP-8, a finding that surprised some clinicians given liraglutide's longer track record. The daily injection burden of liraglutide may contribute to dropout in real-world settings beyond what trial conditions capture.

What STEP-8 Does Not Tell Us

STEP-8 ran for 68 weeks. It does not provide 2-year, 3-year, or 5-year comparative data. Observational and registry studies suggest semaglutide's durability advantage persists at 2 years, but randomized head-to-head data beyond 68 weeks do not yet exist. Clinicians should counsel patients accordingly.

Cardiovascular Outcomes: An Emerging Differentiator

Long-term durability also means long-term risk reduction. Cardiovascular outcome data favor semaglutide in the obesity population.

SELECT Trial Results

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo in adults with established cardiovascular disease and obesity but without diabetes, over a mean follow-up of 39.8 months. [7] This was the first GLP-1 receptor agonist trial to show cardiovascular benefit specifically in the obesity-without-diabetes population. The FDA subsequently approved a cardiovascular risk-reduction indication for Wegovy in March 2024. [5]

Liraglutide Cardiovascular Data

Liraglutide 1.8 mg (Victoza, the diabetes dose) showed cardiovascular benefit in the LEADER trial for patients with type 2 diabetes. [8] The obesity dose of liraglutide 3 mg (Saxenda) does not carry an FDA-approved cardiovascular indication. That distinction matters for patients whose primary driver for treatment is cardiovascular risk reduction rather than weight loss alone.

Comparing Mechanisms: Why the Efficacy Gap Exists

Both drugs activate the glucagon-like peptide-1 receptor, but structural differences between semaglutide and liraglutide create meaningful pharmacologic distinctions.

Half-Life and Receptor Occupancy

Semaglutide's half-life is approximately 165 to 184 hours (roughly 7 days), which allows once-weekly dosing and maintains near-continuous receptor occupancy. [9] Liraglutide's half-life is approximately 13 hours, requiring daily dosing and producing larger peaks and troughs in plasma concentration. Continuous receptor engagement with semaglutide appears to produce stronger and more sustained appetite suppression, as reflected in trial outcomes.

CNS Penetration and Appetite Signaling

Semaglutide has greater CNS penetration than liraglutide based on preclinical data, acting more extensively on hypothalamic and brainstem appetite circuits. [9] This may partly explain the larger reduction in food intake reported by patients on semaglutide. Patients frequently report that cravings decrease more completely on Wegovy than on Saxenda, though this comparison comes from observational reports rather than randomized crossover trials.

Practical Considerations: Dosing, Cost, and Access

Titration Schedules

Semaglutide 2.4 mg requires a 16-week titration: 0.25 mg for 4 weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching 2.4 mg at week 17. Liraglutide 3 mg requires a 5-week titration: 0.6 mg in week 1, increasing by 0.6 mg weekly to reach 3 mg by week 5. Liraglutide reaches its maintenance dose faster. For patients who want rapid titration, that may matter.

Cost and Insurance Coverage

As of mid-2025, the list price for Wegovy is approximately $1,350 per month without insurance; Saxenda lists at approximately $1,400 per month. Real-world out-of-pocket costs vary substantially based on insurance coverage, manufacturer savings programs, and pharmacy benefit design. Neither drug has a generic equivalent. The Wegovy manufacturer savings card can reduce cost to $0 for eligible commercially insured patients. [5]

Storage and Injection Burden

Wegovy uses a prefilled pen with one injection per week. Saxenda uses a prefilled pen requiring daily injection, 365 injections per year versus 52 for Wegovy. In patient preference surveys, weekly dosing is consistently preferred. The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines note that adherence to daily injectable regimens tends to be lower than weekly regimens over 12-month periods. [10]

Should I Switch from Wegovy to Saxenda?

Switching from Wegovy to Saxenda is generally not recommended as a strategy to improve outcomes. The evidence uniformly shows semaglutide outperforms liraglutide on weight loss magnitude, durability, and cardiovascular risk reduction. A switch in that direction is typically considered only when semaglutide is unavailable due to shortage, cost, or intolerable side effects that do not recur with liraglutide.

Reasons a Clinician Might Recommend Switching to Saxenda

Supply disruptions for Wegovy have been documented by the FDA since 2022, periodically limiting access. [5] Some patients experience persistent nausea or gastroparesis-like symptoms on semaglutide that resolve on liraglutide, possibly because liraglutide's shorter half-life produces less sustained gastric-emptying delay. A patient who has lost significant weight on Wegovy and needs to maintain rather than continue losing may find liraglutide's lower efficacy acceptable as a bridge.

How to Transition Clinically

When switching from semaglutide 2.4 mg weekly to liraglutide 3 mg daily, there is no required washout period given semaglutide's long half-life. Most clinicians begin liraglutide at its starting dose of 0.6 mg daily the day after the last semaglutide injection and titrate over 5 weeks to 3 mg. Patients should be counseled to expect reduced appetite suppression and possible partial weight regain compared with semaglutide. No randomized trial has evaluated the optimal switching protocol; current guidance is based on pharmacokinetic principles and clinical consensus.

Switching from Saxenda to Wegovy

This direction is more clinically defensible. A patient who has achieved partial response on Saxenda (say, 6 to 8% weight loss) but has not reached their weight goal may benefit from transitioning to Wegovy. In practice, the last liraglutide dose is given, and semaglutide is started the following day at 0.25 mg weekly, titrating over 16 weeks. Expect additional weight loss of 6 to 10 percentage points based on STEP-8 comparative data. [1]

Real-World Evidence vs. Trial Data

Phase 3 trial populations are selected and monitored; real-world patients are not. Two important real-world observations are worth noting.

A 2023 retrospective analysis using U.S. Insurance claims data (N=over 20,000 GLP-1 initiators) found that 12-month persistence on semaglutide was approximately 57% versus approximately 42% for liraglutide. [11] Patients who persisted were more likely to achieve 5% or greater weight loss. Persistence itself may be both a driver and a marker of efficacy.

The Obesity Medicine Association has published position statements noting that real-world weight loss with GLP-1 receptor agonists tends to be 20 to 30% lower than trial estimates, partly because trial participants receive more intensive behavioral support. [12] Patients starting Wegovy in a typical primary care setting without structured lifestyle counseling should not expect the full 14.9% seen in STEP-1.

Monitoring and Long-Term Management

Both drugs require ongoing monitoring. The Endocrine Society recommends reassessing weight loss response at 16 weeks: patients who have not lost at least 5% of baseline weight on either drug are unlikely to be long-term responders, and medication adjustment or substitution should be considered. [13] Thyroid C-cell tumor risk, a class-wide concern based on rodent data, has not been demonstrated in human trials for either drug, but both carry a boxed warning and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma. [5]

Patients on either agent for more than 2 years should have periodic reassessment of cardiovascular risk factors, HbA1c, and body composition if available. The goal is not a number on the scale but sustained cardiometabolic benefit.